Gatekeeping and trailblazing: The role of biomarkers in novel guidelines for diagnosing Alzheimer's disease
In: BioSocieties: an interdisciplinary journal for social studies of life sciences, Band 13, Heft 1, S. 213-231
ISSN: 1745-8560
5 Ergebnisse
Sortierung:
In: BioSocieties: an interdisciplinary journal for social studies of life sciences, Band 13, Heft 1, S. 213-231
ISSN: 1745-8560
In: Futures: the journal of policy, planning and futures studies, Band 42, Heft 10, S. 1133-1145
In: Futures: the journal of policy, planning and futures studies, Band 42, Heft 10, S. 1133-1146
ISSN: 0016-3287
In: Health, Technology and Society
This book explores international biomedical research and development on the early diagnosis of Alzheimer's disease. It offers timely, multidisciplinary reflections on the social and ethical issues raised by promises of early diagnostics and asks under which conditions emerging diagnostic technologies can be considered a responsible innovation. The initial chapters in this edited volume provide an overview and a critical discussion of recent developments in biomedical research on Alzheimer's disease. Subsequent contributions explore the values at stake in current practices of dealing with Alzheimer's disease and dementia, both within and outside the biomedical domain. Novel diagnostic technologies for Alzheimer's disease emerge in a complex and shifting field, full of controversies. Innovating with care requires a precise mapping of how concepts, values and responsibilities are filled in through the confrontation of practices. In doing so, the volume offers a practice-based approach of responsible innovation that is also applicable to other fields of innovation
Novel technologies for early diagnosis of Alzheimer's disease (AD) will impact the way society views and deals with AD and ageing. However, such "sociocultural" impacts are hardly acknowledged in standard approaches of technology assessment. In this paper, we outline three steps to assess such broader impacts. First, conceptual analysis of the ideas underlying technological developments shows how these technologies redraw the boundary between Alzheimer's disease and normal ageing and between biological and social approaches of ageing. Second, imaginative scenarios are designed depicting different possible futures of AD diagnosis and societal ways to deal with ageing and the aged. Third, such scenarios enable deliberation on the sociocultural impact of AD diagnostic technologies among a broad set of stakeholders. An early, broad, and democratic assessment of innovations in diagnostics of AD is a valuable addition to established forms of technology assessment.
BASE